How is eculizumab resistance managed?

Jun 10, 2024 ... Soliris (eculizumab) is a monoclonal antibody that works to reduce the destruction of red blood cells in people with paroxysmal nocturnal ... Soliris is not expected to affect the aplastic component of anaemia in patients with PNH. Meningococcal Infection. Due to its mechanism of action, the use of ... Feb 15, 2025 ... You will need to receive a meningococcal vaccine at least 2 weeks before you begin your treatment with eculizumab to decrease the risk that you ... Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ... See full prescribing information for Soliris. Soliris™ (eculizumab),. Concentrated solution for intravenous infusion. Initial U.S. Approval: 2007. WARNING: ... May 7, 2019 ... Treatment with eculizumab (Soliris, Alexion Pharmaceuticals) significantly reduces the risk for relapse among patients with AQP4-IgG ... Sep 13, 2024 ... Soliris (eculizumab) is a prescription drug that's used to treat certain rare autoimmune conditions. Soliris is given as an intravenous (IV) infusion by a ... Nov 14, 2024 ... The brand names of the eculizumab biosimilars are Bekemv and Epysqli. They are only available for the treatment of PNH and aHUS in countries which have ... Jan 23, 2024 ... This trial was a phase 3, patient-blinded, randomized control study assessing the impact of eculizumab on the course of acute renal failure in patients with ... It is used by specialist doctors to treat two rare conditions called paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic-uraemic syndrome (aHUS).